Ascent Group LLC bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 8,025 shares of the company's stock, valued at approximately $2,679,000.
A number of other institutional investors have also made changes to their positions in the business. Tidal Investments LLC raised its position in shares of Medpace by 16.2% during the first quarter. Tidal Investments LLC now owns 874 shares of the company's stock worth $353,000 after acquiring an additional 122 shares during the last quarter. Cetera Investment Advisers grew its holdings in Medpace by 235.0% during the 1st quarter. Cetera Investment Advisers now owns 11,494 shares of the company's stock worth $4,645,000 after acquiring an additional 8,063 shares during the period. Cetera Advisors LLC raised its position in shares of Medpace by 162.4% during the 1st quarter. Cetera Advisors LLC now owns 2,608 shares of the company's stock valued at $1,054,000 after acquiring an additional 1,614 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Medpace by 58.4% in the 2nd quarter. GAMMA Investing LLC now owns 236 shares of the company's stock valued at $97,000 after purchasing an additional 87 shares during the period. Finally, CWM LLC boosted its position in shares of Medpace by 38.8% in the 2nd quarter. CWM LLC now owns 2,323 shares of the company's stock worth $957,000 after purchasing an additional 649 shares during the last quarter. 77.98% of the stock is owned by institutional investors.
Medpace Trading Down 0.3 %
Shares of Medpace stock traded down $1.07 during trading on Tuesday, reaching $341.29. The stock had a trading volume of 58,412 shares, compared to its average volume of 283,038. The company has a market capitalization of $10.61 billion, a price-to-earnings ratio of 29.98, a P/E/G ratio of 1.88 and a beta of 1.37. The stock has a fifty day moving average price of $337.43 and a two-hundred day moving average price of $370.62. Medpace Holdings, Inc. has a 52 week low of $273.14 and a 52 week high of $459.77.
Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating the consensus estimate of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The firm had revenue of $533.32 million for the quarter, compared to analysts' expectations of $540.99 million. During the same quarter in the previous year, the business posted $2.22 EPS. The business's quarterly revenue was up 8.3% compared to the same quarter last year. On average, equities analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.
Analysts Set New Price Targets
Several equities analysts have weighed in on MEDP shares. StockNews.com lowered Medpace from a "buy" rating to a "hold" rating in a research note on Friday, September 27th. Jefferies Financial Group lowered shares of Medpace from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $415.00 to $345.00 in a research note on Wednesday, September 25th. Baird R W downgraded shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. Truist Financial reduced their price target on shares of Medpace from $415.00 to $397.00 and set a "hold" rating on the stock in a research report on Monday, October 14th. Finally, William Blair reaffirmed an "outperform" rating on shares of Medpace in a research note on Tuesday, October 22nd. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $380.56.
Read Our Latest Stock Report on MEDP
Medpace Profile
(
Free Report)
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
See Also
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.